Literature DB >> 21675833

The potential for LOXL2 as a target for future cancer treatment.

Holly E Barker, Janine T Erler.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21675833     DOI： 10.2217/fon.11.46

Source DB:  PubMed          Journal:  Future Oncol        ISSN： 1479-6694            Impact factor:   3.404


× No keyword cloud information.
  8 in total

Review 1.  Novel insights into the function and dynamics of extracellular matrix in liver fibrosis.

Authors:  Morten A Karsdal; Tina Manon-Jensen; Federica Genovese; Jacob H Kristensen; Mette J Nielsen; Jannie Marie B Sand; Niels-Ulrik B Hansen; Anne-Christine Bay-Jensen; Cecilie L Bager; Aleksander Krag; Andy Blanchard; Henrik Krarup; Diana J Leeming; Detlef Schuppan
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2015-03-12       Impact factor: 4.052

Review 2.  Extracellular matrix remodeling: the common denominator in connective tissue diseases. Possibilities for evaluation and current understanding of the matrix as more than a passive architecture, but a key player in tissue failure.

Authors:  Morten A Karsdal; Mette J Nielsen; Jannie M Sand; Kim Henriksen; Federica Genovese; Anne-Christine Bay-Jensen; Victoria Smith; Joanne I Adamkewicz; Claus Christiansen; Diana J Leeming
Journal:  Assay Drug Dev Technol       Date:  2012-10-09       Impact factor: 1.738

3.  Detection of Lysyl Oxidase-Like 2 (LOXL2), a Biomarker of Metastasis from Breast Cancers Using Human Blood Samples.

Authors:  Metini Janyasupab; Ying-Hui Lee; Yuan Zhang; Chen W Liu; Jieyi Cai; Adriana Popa; Anna C Samia; Kuan W Wang; Jiaqiang Xu; Chi-Chang Hu; Michael K Wendt; Barbara J Schiemann; Cheryl L Thompson; Yun Yen; William P Schiemann; Chung C Liu
Journal:  Recent Pat Biomark       Date:  2015

Review 4.  Epithelial to mesenchymal transition in head and neck squamous cell carcinoma.

Authors:  Ashley Smith; Theodoros N Teknos; Quintin Pan
Journal:  Oral Oncol       Date:  2012-11-19       Impact factor: 5.337

Review 5.  Emerging drugs for myelofibrosis.

Authors:  Ehab Atallah; Srdan Verstovsek
Journal:  Expert Opin Emerg Drugs       Date:  2012-12       Impact factor: 4.191

Review 6.  The rationale for targeting the LOX family in cancer.

Authors:  Holly E Barker; Thomas R Cox; Janine T Erler
Journal:  Nat Rev Cancer       Date:  2012-07-19       Impact factor: 60.716

7.  The histone demethylase KDM4B regulates peritoneal seeding of ovarian cancer.

Authors:  C Wilson; L Qiu; Y Hong; T Karnik; G Tadros; B Mau; T Ma; Y Mu; J New; R J Louie; S Gunewardena; A K Godwin; O W Tawfik; J Chien; K F Roby; A J Krieg
Journal:  Oncogene       Date:  2016-11-21       Impact factor: 9.867

8.  LOXL2 induces aberrant acinar morphogenesis via ErbB2 signaling.

Authors:  Joan Chang; Monica M Nicolau; Thomas R Cox; Daniel Wetterskog; John W M Martens; Holly E Barker; Janine T Erler
Journal:  Breast Cancer Res       Date:  2013       Impact factor: 6.466
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.